Posted by Michael Wonder on 14 Aug 2019
Canadians benefitting from substantially lower generic drug prices
14 August 2019 - Latest agreement between public payers and the Canadian generic industry closes gap with international prices.
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Generics360 report finds that government policies have significantly reduced the prices for generic drugs in recent years, resulting in important savings for Canadians.
Since 2007, the PMPRB has been monitoring and reporting changes in the Canadian generic landscape to support public and private drug plans in their efforts to make sustainable pricing, purchasing and reimbursement decisions. Over the past decade, the pan-Canadian Pharmaceutical Alliance (pCPA) has made a concerted effort to lower generic drug prices in Canada. The most recent agreement between the pCPA and the Canadian Generic Pharmaceutical Alliance (CGPA) effectively closes the gap between Canadian and international prices.
